Jobs — They must’ve put Oprah Winfrey in charge of the labor department last month because everybody is getting a job. The U.S. economy added 531,000 jobs in October, smashing last month's numbers as well as economist expectations. Furthermore, numbers from both the August and September labor reports were revised upward - by a lot. Not only is this a great sign for Main Street USA, but gives us even more firing power for insulting economists.

September’s somewhat concerning original number clocked job additions at +194,000. Now, that figure has been revised up to +312,000, an addition of 118,000 jobs. August’s figure was jacked up to +483,000 from +366,000, an additional 117,000. Counting is hard, but something tells me professional economists in the largest and most advanced economy in the history of the world should be able to do a little better. 

As for October, expectations placed additions at +450,000, coming in 81,000 below the reported figure. Meanwhile, unemployment fell further from 4.8% to 4.6%, a new low since the start of the pandemic and another example of economists being wrong. 

Basically, the economy is firing on all cylinders. It’s a good time to be an American. However, keep in mind, a strong job market gives JPow a green light to raise rates sooner rather than later, but we’ll have to wait until December 15th to hear his thoughts. Until then, keep raking in the dough.

Airbnb ($ABNB) — Airbnb went public during a tough time in their industry, but resilience pays off, both literally and figuratively in this last quarter. Revenue grew 67% from the same period last year to $2.24bn, while net income stole the show, skyrocketing 280% to $834mm. Shares surged on the report, climbing 13% to close the week.

Pfizer ($PFE) — Saving the world once wasn’t enough for the team at Pfizer. The firm behind the pandemic-healing vaccine has come out with exciting data around its new COVID medicine, and shares were duly paid, gaining 10.9% on Friday. Pfizer announced that its experimental antiviral pill targeting COVID-19 reduced hospitalization and death in high-risk adults by upwards of 90%. In addition to completing the best double-whammy in history, Pfizer is finding more ways to profit off the pandemic. Win, win, right?

Peloton ($PTON) — The company behind one of the world’s preeminent exercise bikes has had one of the more unusual - and volatile - last 12 months. Friday did not help to ease that reputation. Shares plunged 35.3% after Q3 earnings revealed revenue barely grew 6% YoY and the company’s core business line of bikes and treads fell 17%. Definitely not what I would call a healthy report, but Planet Fitness was loving it, gaining over 15% since Wednesday’s close. 

Moderna ($MRNA) — One man’s trash is another man’s treasure, and while Pfizer was certainly treasure last week, Moderna was nothing short of complete trash. Shares in the now, household-name biotech firm plummeted 15.6% on Friday after vaccine sales came in $1bn short of analyst expectations for the quarter, clocking in at $4.8bn. Shares are now down over 50% from their peak and some bargain hunting analysts smell a deal.